Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

A new study finds no significant differences in cardiovascular and thromboembolic risks among biologics for psoriasis or ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...

QX004N, an interleukin-23 inhibitor, showed safety and efficacy in the treatment of moderate to severe plaque psoriasis, according to a study. As AI is integrated into health care, clinicians can ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

To demonstrate the efficacy of targeting interleukin 6 receptor in patients with Sjögren’s syndrome-related systemic complications. Methods Multicentre double-blind randomised placebo-controlled trial ...

Through cytokine screening, we identified that interleukin-1β (IL-1β), a key mediator of inflammation, inhibits syncytia formation mediated by various SARS-CoV-2 strains. Mechanistically, IL-1β ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...

Although RA is associated with significant morbidity, the increasing number of effective drugs and modes of action has improved the disease outcome. Currently, several US Food and Drug Administration ...